{"url_path":"/sec/antx/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1880438/0001193125-26-344549-index.html","accession_number":"0001193125-26-344549","cik":"0001880438","ticker":"ANTX","issuer_name":"AN2 Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1880438/0001193125-26-344549-index.html","primary_entity_key":"0001880438","primary_entity_name":"AN2 Therapeutics, Inc."},"word_count":129,"has_tables":true,"body_markdown":"## Item 2.02 Results of Operations and Financial Condition.\n\nOn August 11, 2026, AN2 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\n\n \n\nAll of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing."}